In vivo imaging neurotransmitter function: The rat 6-hydroxydopamine model and its relevance for human Parkinson's disease

NuklearMedizin

Volumn 50, Issue 4, 2011, Pages 155-166

  Nikolaus, S ^a   Larisch, R ^b   Vosberg, H ^a   Beu, M ^a   Hautzel, H ^a   Wirrwar, A ^a   Mueller, H W ^a   Antke, C ^a  

^a UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

^b Clinic of Nuclear Medicine   (Germany)

Author keywords

6 hydroxydopamine model; Dopamine; Parkinson's disease; PET; Small animal imaging; SPECT

Indexed keywords

2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 HYDROXYBENZYLHYDRAZINE; 3BETA (4 FLUOROPHENYL) 2BETA TROPANECARBOXYLIC ACID METHYL ESTER; 6 FLUORODOPAMINE F 18; APOMORPHINE; BENSERAZIDE PLUS LEVODOPA; CANNABINOID 1 RECEPTOR; CARBIDOPA PLUS LEVODOPA; CARBON 11; DIHYDROTETRABENAZINE; DOPAMINE; DOPAMINE 2 RECEPTOR; DOPAMINE TRANSPORTER; FLUORINE 18; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; LEVODOPA; META TYROSINE; METABOTROPIC RECEPTOR 5; METHAMPHETAMINE; METHYLPHENIDATE; OXIDOPAMINE; PRAMIPEXOLE; RACLOPRIDE C 11; SEROTONIN; SEROTONIN TRANSPORTER; VESICULAR MONOAMINE TRANSPORTER 2;

CATECHOLAMINE METABOLISM; CAUDATE NUCLEUS; DISEASE COURSE; DISEASE MODEL; DOPAMINE METABOLISM; DOPAMINERGIC SYSTEM; DRUG RECHALLENGE; HIPPOCAMPUS; HUMAN; IDIOPATHIC DISEASE; IN VIVO STUDY; MEDIAL FOREBRAIN BUNDLE; MESENCHYMAL STEM CELL TRANSPLANTATION; NEOCORTEX; NEOSTRIATUM; NEUROTRANSMISSION; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRESYNAPTIC NERVE; PUTAMEN; RECEPTOR BINDING; REVIEW; SCINTILLATION CAMERA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA;

ANIMALS; BRAIN; DISEASE MODELS, ANIMAL; HUMANS; MOLECULAR IMAGING; NEUROTRANSMITTER AGENTS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; TISSUE DISTRIBUTION;

EID: 80051631646     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/Nukmed-0371-10-12     Document Type: Review

References (55)

1. Björklund LM, Sanchez-Pernaute R, Chung S et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci USA 2002; 99: 2344-2349.
2. Bohnen NI, Albin RL, Koeppe RA et al. Positron emission tomography of monoaminergic vesicular binding in aging and Parkinson disease. J Cereb Blood Flow Metab 2006; 26:1198-1212.
3. Booij J, de Bruin K, Habraken JB et al. Imaging of dopamine transporters in rats using high-resolution pinhole single-photon emission tomography. Eur J Nucl Med Mol Imaging 2002; 29: 1221-1224.
4. Brotchie JM. CB1 cannabinoid receptor signalling in Parkinson's disease. Curr Opin Pharmacol 2003; 3: 54-61.
5. Brownell AL, Livni E, Galpern W, Isacson W. In vivo PET imaging in rat of dopamine terminals reveals functional neural transplants. Ann Neurol 1998; 43: 387-390.
6. Casteels C, Vermaelen P, Nuyts J et al. Construction and evaluation of multitracer small-animal PET probabilistic atlases for voxel-based functional mapping of the rat brain. J Nucl Med 2006; 47: 1858-1866.
7. Casteels C, Lauwers E, Baitar A et al. In vivo type 1 cannabinoid receptor mapping in the 6-hydroxydopamine lesion rat model of Parkinson's disease. Brain Res 2010; 1316: 153-262.
8. Caudle WM, Zhang J. Glutamate, excitotoxicity, and programmed cell death in Parkinson disease. Exp Neurol 2009; 220:2 30-33.
9. Chen YCI, Galpern WR, Brownell AL et al. Detection of dopaminergic neurotransmitter activity using pharmacologic MRI: correlation with PET, microdialysis, and behavioral data. Magn Reson Med 1997; 38: 389-398.
10. Chen YI, Brownell AL, Galpern W et al. Detection of dopaminergic cell loss and neural transplantation using pharmacological MRI, PET and behavioral assessment. Neuroreport 1999; 10: 2881-2886.
11. Cicchetti F, Brownell AL, Williams K et al. Neuro - inflammation of the nigrostriatal pathway during progressive 6-OHDA dopamine degeneration in rats monitored by immunohistochemistry and PET imaging. Eur J Neurosci 2002; 15: 991-998.
12. Collantes M, Penuelas I, Alvarez-Erviti L et al. Use of 11C-(+)-alpha -dihydrotetrabenazine for the assessment of dopaminergic innervation in animal models of Parkinson's disease. Rev Esp Med Nucl 2008; 27: 103-111.
13. Cumming P, Ase A, Diksic M et al. Metabolism and blood-clearanceof L-3,4-dihydroxy-[3H]phenylalanine [3H]DOPAand 6-{18F]fluoro-L-DOPA in the rat. Biochem Pharmacol 1995; 50: 943-946.
14. Duty S. Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease. Br J Pharmacol 2010; 161: 271-287.
15. Ferré S, Fuxe K. Dopamine denervation leads to an increase in the intramembrane interactions between adenosine A2 and dopamine D2 receptors in the neostriatum. Brain Res 1992; 595: 124-130.
16. Fox SH, Chuang R, Brotchie JM. Serotonin and Parkinson's disease: On movement, mood, and madness. Mov Disord 2009; 24: 1255-1266.
17. Honer M, Hengerer B, Blagoev M et al. Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice. Nucl Med Biol 2006; 33: 607-614.
18. Hume SP, Opacka-Juffry J, Myers R et al. Effect of L-dopa and 6-hydroxydopamine lesioning on [11C]raclopride binding in rat striatum quantified using PET. Synapse 1995; 21: 45-53.
19. Hume SP, Lammertsma AA, Myers R et al. The potential of high-resolution positron emission tomography to monitor striatal dopaminergic function in rat models of disease. J Neurosci Meth 1996; 67: 103-112.
20. Inaji M, Okauchi T, Ando K et al. Correlation between quantitative imaging and behavior in unilaterally 6-OHDA-lesioned rats. Brain Res 2005; 1064: 136-145.
21. Inaji M, Yoshizaki T, Okauchi T et al. In vivo PET measurements with [11C]PE2I to evaluate fetal mes - encephalic transplantations to unilateral 6-OHDAlesioned rats. Cell Transplant 2005; 14: 655-663.
22. Jackson J, Chapon C, Jones W et al. In vivo multimodal imaging of stem cell transplantation in a rodent model of Parkinson's disease. J Neurosci Methods 2009; 183: 141-148.
23. Jordan S, Eberling JL, Bankiewicz KS et al. 6-[18F] fluoro- L-m-tyrosine: metabolism, positron emission tomography kinetics, and 1-methyl- 4-phenyl-1,2,3,6-tetrahydropyridine lesions in primates. Brain Res 1997; 750: 264-276.
24. Klein RL, Dayton RD, Terry TL et al. PET imaging in rats to discern temporal onset differences between 6-hydroxydopamine and tau gene vector neurodegeneration models. Brain Res 2009; 1259: 113-122.
25. Kuhar MJ, Couceyro PR, Lambert PD. Catechol - amines. In: Siegel GJ, Agranoff BW, Albers RW, Fisher SK, Whler MD (eds). Basic Neurochemistry - Molecular, Cellular and Medical Aspects. Balti - more: Lippincott, Williams & Wilkins, 1998; 243-261.
26. Nguyen TV, Brownell AL, Chen YCI et al. Detection of the effects of dopamine receptor sensitivity using pharmacological MRI and correlations with PET. Synapse 2000; 36: 57-65.
27. Nikolaus S, Huston JP, Körber B et al. Pretreatment with neurokinin substance P but not with chole - cystokinin-8S can alleviate functional deficits of partial nigrostriatal 6-hydroxydopamine lesion. Peptides 1997; 18: 1161-1168.
28. Nikolaus S, Huston JP, Schwarting RKW. Pretreatment with fragments of substance-P or with cholecystokinin differentially affects revovery from subtotal nigrostriatal 6-hydroxydopamine lesion. Neural Plast 1999; 6: 77-89.
29. Nikolaus S, Larisch R, Beu M et al. Imaging of striatal dopamine D2 receptors with a PET system for small laboratory animals in comparison with storage phosphor autoradiography: a validation study with [18F]N-methyl-benperidol. J Nucl Med 2001; 42: 1691-1661.
30. Nikolaus S, Larisch R, Beu M et al. Bilateral increase in striatal dopamine D2 receptor density in the 6-hydroxydopamine-lesioned rat: a serial in vivo investigation with small animal PET. Eur J Nucl Med Mol Imaging 2003; 30: 390-395.
31. Nikolaus S, Larisch R, Beu M et al. In vivo measurement of D2 receptor density and affinity for 18F-(3- N- methyl)benperidol in the rat striatum with a PET system for small laboratory animals. J Nucl Med 2003; 44: 618-624.
32. Nikolaus S, Beu M, Wirrwar A et al. The contribution of small animal positron emission tomography to the neurosciences - a critical evaluation. Rev Neurosci 2004; 15: 131-156.
33. Nikolaus S, Wirrwar A, Antke C et al. Stand der Kleintierbildgebung mit hochauflösender SPECT. Nuklearmedizin 2005; 6: 257-266.
34. Nikolaus S, Antke C, Kley K et al. Investigating the dopaminergic synapse in vivo. I. Molecular imaging studies in humans. Rev Neurosci 2007; 18: 439-472.
35. Nikolaus S, Larisch R, Beu M et al. Investigating the dopaminergic synapse in vivo. II. Molecular imaging studies in small laboratory animals. Rev Neurosci 2007; 18: 473-505.
36. Nikolaus S, Antke C, Müller HW. In vivo imaging of synaptic function in the central nervous system. I. Movement disorders and dementia. Behav Brain Res 2009; 204: 1-31.
37. Nikolaus S, Antke C, Müller HW. In vivo imaging of synaptic function in the central nervous system. II. Mental and affective disorders. Behav Brain Res 2009; 204; 32-66.
38. Nikolaus S, Beu M, Antke C, Müller HW. Cortical GABA, striatal dopamine and midbrain serotonin as the key players in compulsive and anxiety disorders - Results from in vivo imaging studies. Rev Neurosci 2010; 21: 119-139.
39. Opacka-Juffry J, Ashworth S, Hume SP et al. GDNF protects against 6-hydroxydopamine lesion: in vivo study with microdialysis and PET. Neuroreport 1995; 7: 348-352.
40. Opacka-Juffry J, Ashworth S, Sullivan AM et al. Lack of permanent nigrostriatal dopamine deficit following 6-hydroxydopamine injection into the rat striatum. J Neural Transm 1996; 103: 1429-1434.
41. Pellegrino D, Cicchetti F, Wang X et al. Modulation of dopaminergic and glutamatergic brain function: PET studies on parkinsonian rats. J Nucl Med 2007; 48: 1147-1153.
42. Pritzel M, Huston JP, Sarter M. Behavioral and neuronal reorganization after unilateral substantia nigra lesions: evidence for increased interhemispheric nigrostriatal projections. Neuroscience 1983; 9: 879-888.
43. Santiago RM, Barbieiro J, Lima MMS et al. Depressive- like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson's disease are predominantly associated with serotonin and dopamine. Prog Neuropsychopharmacol Biol Psychiat 2010; 34: 1140-1114.
44. Scherfler C, Donnemiller E, Schocke M et al. Evaluation of striatal dopamine transporter function in rats by in vivo beta-[123I]CIT pinhole SPECT. Neuro image 2002; 17: 128-141.
45. Schramm NU, Ebel G, Engeland U et al. High-resolution SPECT using multipinhole collimation. IEEE Trans Nucl Sci 2003; 50: 315-320.
46. Schwarting RKW, Huston JP. The unilateral 6- hydroxy dopamine lesion model in behavioral brain research. Analysis of functional deficits, recovery and treatments. Prog Neurobiol 1996; 50: 275-331.
47. Sossi V, Holden JE, Topping GJ et al. In vivo measurement of density and affinity of the monoamine vesicular transporter in a unilateral 6-hydroxydopamine rat model of PD. J Cereb Blood Flow Metab 2007; 27: 1407-1415.
48. Sossi V, Dinelle K, Topping GJ et al. Dopamine transporter relation to levodopa-derived synaptic dopamine in a rat model of Parkinson's: an in vivo imaging study. J Neurochem 2009; 109: 85-92.
49. Sossi V, Dinelle K, Schulzer M et al. Levodopa and pramipexole effects on presynaptic dopamine PET markers and estimated dopamine release. Eur J Nucl Med Mol Imaging 2010; 37: 2364-2370.
50. Strome EM, Cepeda IL, Sossi V, Doudet DJ. Evaluation of the integrity of the dopamine system in a rodent model of Parkinson's disease: small animal positron emission tomography compared to behavioral assessment and autoradiography. Mol Imaging Biol 2006; 8: 292-299.
51. Sullivan AM, Opacka-Juffry J, Blunt SB. Long-term protection of the rat nigrostriatal dopaminergic system by glial cell line-derived neurotrophic factor against 6-hydroxydopamine in vivo. Eur J Neurosci 1998; 10: 57-63.
52. Sun W, Sugiyama K, Fang X et al. Different striatal D2-like receptor function in an early stage after unilateral striatal lesion and medial forebrain bundle lesion in rats. Brain Res 2010; 1317: 227-235.
53. Wang JL, Shunichi O, Parhi AK et al. In vivo studies on SERT-selektive [18F]FPBM and VMAT2-selective [18F]AV-133 radiotracers in a rat model of Parkinson's disease. Nucl Med Biol 2010; 37: 479-486.
54. Wu C, van der Have F, Vastenhouw B et al. Absolute quantitative total-body small-animal SPECT with focusing pinholes. Eur J Nucl Med Mol Imaging 2010; 37: 2127-2135.
55. Zhu A, Wang X, Yu M et al. Evaluation of four pyridine analogs to characterize 6-OHDA-induced modulation of mGluR5 function in rat brain using microPET studies.J Cereb Blood Flow Metab 2007; 27: 1623-1631.